Timothy Watson received his B.A. in chemistry from Wittenberg University in 1989 and his Ph.D. from The Ohio State University in 1994 under the direction of Leo Paquette. Watson joined Marion Merrell Dow in Chemical Research and Development as a process chemist in July of 1994 where some of his responsibilities involved developing new API processes, manufacturing the first GMP API bulk, and technology transfers (early development and the discovery chemistry interface). During this time, Marion Merrell Dow merged a few times to form Hoechst Marion Roussel, and ultimately Aventis. Watson joined Pfizer in June of 2000 where he continued with process chemistry development responsibilities with a focus on post proof of concept projects (Phase II and III technology and strategy). In 2004, he joined the Pfizer Full Development group as a API project leader responsible for chemical process development, technology transfer to commercial manufacturing facilities, regulatory CMC writing, strategy, and preparation. Watson joined Global CMC in 2009 and continues to support all QbD programs with his API development and manufacturing expertise as an Associate Research Fellow. He is currently a Pfizer representative with ISPE, AIChE, and PhRMA (ICHQ11) on multiple QbD team efforts.